New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open label extension ...

Myasthenia gravis (MG) is a neuromuscular junction disorder clinically characterized by fluctuating muscle weakness, in which some patients with respiratory muscle weakness are at risk of progressing ...

The Shanghai Auto Show – motor show in UK and European-speak – has been growing in significance over the last decade. It’s no longer considered a local show full of domestic debuts ...

The opioid crisis emergency declaration has been extended, with overdose deaths declining by 25% due to fewer synthetic opioid fatalities. Overdose deaths remain high compared to a decade ago ...

Responders to batoclimab in Period 1, defined as ≥2-point improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) score from baseline, were re-randomized 1:1:1 to batoclimab (340mg ...

The STEER study showed significant motor function improvement in children with SMA using intrathecal onasemnogene abeparvovec. The primary efficacy endpoint was met with a 2.39-point improvement ...

Indeed, although the trial missed its secondary endpoints, intrathecal (IT) Zolgensma (onasemnogene abeparvovec or OAV101 IT) elicited a 2.39-point improvement on the Hammersmith Functional Motor ...

"All three types of myasthenia gravis, based on antibody status ... In LRP4 disease, "false positives can be seen with motor neuron disease," he said. "I recommend always having neurophysiological ...